DBV Technologies pulls peanut allergy treatment from FDA review
by Adam Feuerstein
Dec 19, 2018
1 minute
DBV Technologies is withdrawing its marketing application for a peanut allergy therapy following discussions with the Food and Drug Administration, the
You’re reading a preview, subscribe to read more.
Start your free 30 days